Sign in
ALLO Stock Price, Chart, Stats & News
Allogene Therapeutics, Inc.
Save
451.16M
Market cap
–
Current P/E
–
Forward P/E
ALLO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -45.90% |
ROE | -57.07% |
D/E | 0.28x |
Interest coverage ratio | -194.71x |
ALLO valuation
P/E | – |
P/S | – |
P/B | 1.70x |
P/CF | -3.34x |
P/FCF | -3.68x |
P/OCF | -3.34x |
PEG | -0.23x |
EV multiple | -2.86x |
About
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma.
Similar securities
Based on sector and market capitalization
Report issue